RSLV132 | RNA hydrolysis | Phase II | Systemic lupus erythematosusSjögren's syndrome |
SM101 | Anti-immune complex | Phase II | Systemic lupus erythematosusLupus nephritis |
BIIB059 | Anti-BDCA2 (pDCs) | Phase II | Systemic lupus erythematosus |
MEDI-7734 | Anti-ILT7 (pDCs) | Phase I | DermatomyositisPolymyositisSystemic sclerosisSjögren's syndromeSystemic lupus erythematosus |
JNJ-55920839 | Anti-IFN-α/ω | Phase I | Systemic lupus erythematosus |
AGS-009 | Anti-IFN-α | Phase I*
| Systemic lupus erythematosus |
IFN-α-kinoid | Anti-IFN-α | Phase II | Dermatomyositis |
Phase II | Systemic lupus erythematosus |
Anifrolumab | Anti-IFNAR1 | Phase II | Lupus nephritisSjögren's syndrome |
Phase III | Systemic lupus erythematosus |
Baricitinib†
| JAK1/JAK2 inhibitor | Phase II | Systemic lupus erythematosus |
PF-04965842 | JAK1 inhibitor | Phase II | Systemic lupus erythematosus |